ATHA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 14.90%

Insider Buying (Last 12 Months): $397,383.84

Insider Selling (Last 12 Months): $0.00

Athira Pharma Insider Trading History Chart

Athira Pharma Share Price & Price History

^$1.97

▲ +0.1 (5.35%)

As of 12/8/2023 01:00 AM ET

Days: 30 | 90 | 365

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

Invest in Autonomix today.

Athira Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/7/2023	Andrew Gengos	Insider	Buy	15,000	$3.43	$51,450.00	80,012
6/5/2023	Andrew Gengos	Insider	Buy	45,000	$3.00	$135,000.00	65,012
6/2/2023	Andrew Gengos	Insider	Buy	20,012	$2.82	$56,433.84	20,012
3/29/2023	James A Johnson	Director	Buy	5,000	$2.40	$12,000.00	5,000
12/28/2022	Glenna Mileson	CFO	Buy	50,000	$2.85	$142,500.00	159,930
12/2/2022	Kelly A Romano	Director	Buy	30,000	$3.29	$98,700.00	38,315
11/15/2022	Hans Moebius	Insider	Buy	5,000	$3.29	$16,450.00	65,836
6/29/2022	Perceptive Advisors Llc	Director	Buy	270,000	$2.99	$807,300.00	3,695,916
6/28/2022	Hans Moebius	Insider	Buy	10,000	$2.88	$28,800.00	52,955
6/23/2022	Mark James Litton	CEO	Sell	7,960	$2.69	$21,412.40	128,555
6/23/2022	Mark Worthington	General Counsel	Sell	2,614	$2.69	$7,031.66	19,097
6/23/2022	Rachel Lenington	COO	Sell	4,193	$2.69	$11,279.17	5,807
3/31/2022	Kelly A Romano	Director	Buy	8,000	$13.11	$104,880.00
1/25/2021	Perceptive Advisors Llc	Director	Buy	311,111	$22.50	$6,999,997.50

Trading Experts Call It “The Perfect Tesla Trade”

From Wealthpress | Ad

Click here for details,

SEC Filings (Institutional Ownership Changes) for Athira Pharma (NASDAQ:ATHA)

62.74% of Athira Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Athira Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/30/2023	American Century Companies Inc.	15,269	$31K	0.0%	N/A	0.040%
11/17/2023	Jacobs Levy Equity Management Inc.	299,661	$0.61M	0.0%	+49.3%	0.787%
11/15/2023	GSA Capital Partners LLP	297,052	$0.60M	0.1%	-14.3%	0.780%
11/15/2023	Laird Norton Trust Company LLC	178,709	$0.36M	0.0%	+21.3%	0.470%
11/14/2023	Nan Fung Group Holdings Ltd	180,000	$0.36M	0.3%	+1,429.4%	0.473%
11/13/2023	Acadian Asset Management LLC	139,542	$0.28M	0.0%	-43.0%	0.367%
11/9/2023	UBS Group AG	99,502	$0.20M	0.0%	+251.6%	0.261%
11/7/2023	Barclays PLC	435,841	$0.88M	0.0%	+99.1%	1.145%
10/27/2023	Marquette Asset Management LLC	30,783	$62K	0.0%	N/A	0.081%
10/27/2023	Acuitas Investments LLC	149,600	$0.30M	0.2%	N/A	0.393%
10/23/2023	BML Capital Management LLC	1,704,362	$3.44M	3.2%	-8.6%	4.478%
10/19/2023	Clarius Group LLC	39,427	$80K	0.0%	N/A	0.104%
8/21/2023	Osaic Holdings Inc.	146,969	$0.43M	0.0%	+7.1%	0.386%
8/15/2023	Wells Fargo & Company MN	12,834	$38K	0.0%	-31.1%	0.034%
8/15/2023	Y Intercept Hong Kong Ltd	37,289	$0.11M	0.0%	N/A	0.098%
8/15/2023	Goldman Sachs Group Inc.	17,416	$51K	0.0%	-86.6%	0.046%
8/15/2023	Point72 Asset Management L.P.	905,405	$2.67M	0.0%	N/A	2.379%
8/15/2023	Stifel Financial Corp	24,800	$73K	0.0%	-26.2%	0.065%
8/14/2023	Potomac Capital Management Inc.	74,585	$0.22M	0.2%	-6.8%	0.196%
8/14/2023	Ergoteles LLC	33,600	$99K	0.0%	N/A	0.088%
8/14/2023	State of Wisconsin Investment Board	24,500	$72K	0.0%	-41.9%	0.064%
8/14/2023	State Street Corp	118,481	$0.35M	0.0%	-84.9%	0.311%
8/14/2023	Prelude Capital Management LLC	28,722	$85K	0.0%	-33.1%	0.075%
8/11/2023	Renaissance Technologies LLC	438,800	$1.29M	0.0%	+40.7%	1.156%
8/11/2023	Nan Fung Group Holdings Ltd	11,769	$35K	0.0%	N/A	0.031%
8/11/2023	BlackRock Inc.	669,768	$1.98M	0.0%	-70.5%	1.765%
8/11/2023	Geode Capital Management LLC	293,532	$0.87M	0.0%	-53.6%	0.773%
8/11/2023	Northern Trust Corp	57,418	$0.17M	0.0%	-79.5%	0.151%
8/10/2023	Osaic Holdings Inc.	146,969	$0.43M	0.0%	+7.1%	0.387%
8/10/2023	Charles Schwab Investment Management Inc.	13,857	$41K	0.0%	-85.4%	0.037%
8/9/2023	Dimensional Fund Advisors LP	417,647	$1.23M	0.0%	+19.5%	1.100%
8/7/2023	Acadian Asset Management LLC	244,819	$0.72M	0.0%	-33.3%	0.645%
8/3/2023	Barclays PLC	218,908	$0.65M	0.0%	-7.3%	0.575%
8/3/2023	Bank of New York Mellon Corp	16,278	$48K	0.0%	-85.3%	0.043%
7/31/2023	Brighton Jones LLC	32,200	$95K	0.0%	N/A	0.085%
6/1/2023	Prelude Capital Management LLC	42,957	$0.11M	0.0%	-31.5%	0.113%
5/22/2023	Ameriprise Financial Inc.	11,636	$29K	0.0%	-66.3%	0.031%
5/18/2023	JPMorgan Chase & Co.	27,038	$67K	0.0%	+31.9%	0.071%
5/16/2023	Geode Capital Management LLC	632,348	$1.58M	0.0%	+4.9%	1.667%
5/16/2023	Baker BROS. Advisors LP	2,350,355	$5.88M	0.0%	+25.0%	6.194%
5/15/2023	Two Sigma Advisers LP	494,200	$1.24M	0.0%	+48.8%	1.302%
5/15/2023	Two Sigma Investments LP	421,405	$1.05M	0.0%	+23.8%	1.111%
5/15/2023	Deutsche Bank AG	32,770	$82K	0.0%	+139.0%	0.086%
5/12/2023	Renaissance Technologies LLC	311,865	$0.78M	0.0%	+279.9%	0.822%
5/12/2023	BlackRock Inc.	2,271,458	$5.68M	0.0%	-3.9%	5.986%
5/12/2023	Bank of America Corp DE	473,639	$1.18M	0.0%	+1.0%	1.248%
5/12/2023	UBS Group AG	23,487	$59K	0.0%	-77.2%	0.062%
5/12/2023	Dimensional Fund Advisors LP	349,499	$0.87M	0.0%	+1,200.2%	0.921%
5/12/2023	Panagora Asset Management Inc.	148,803	$0.37M	0.0%	+30.9%	0.392%
5/12/2023	Charles Schwab Investment Management Inc.	95,097	$0.24M	0.0%	+7.1%	0.251%
5/11/2023	Acadian Asset Management LLC	366,915	$0.92M	0.0%	+176.9%	0.967%
5/11/2023	Cornercap Investment Counsel Inc.	75,253	$0.19M	0.0%	N/A	0.198%
5/11/2023	Bristlecone Advisors LLC	85,306	$0.21M	0.0%	-87.8%	0.225%
5/10/2023	Simplify Asset Management Inc.	1,390,148	$3.48M	0.5%	N/A	3.664%
5/8/2023	Federated Hermes Inc.	10,581	$26K	0.0%	+60.6%	0.028%
5/8/2023	Bailard Inc.	33,894	$85K	0.0%	-24.8%	0.089%
5/4/2023	Barclays PLC	236,118	$0.59M	0.0%	+13.5%	0.622%
5/2/2023	Sargent Investment Group LLC	20,272	$51K	0.0%	+34.1%	0.053%
4/28/2023	SG Americas Securities LLC	19,512	$49K	0.0%	+63.6%	0.051%
4/17/2023	Clarius Group LLC	38,000	$95K	0.0%	+15.8%	0.100%
4/14/2023	BML Capital Management LLC	1,864,907	$4.66M	4.0%	+160.9%	4.915%
2/16/2023	Alliancebernstein L.P.	81,900	$0.26M	0.0%	+6.9%	0.216%
2/15/2023	Public Employees Retirement System of Ohio	27,303	$87K	0.0%	-18.5%	0.072%
2/15/2023	Jane Street Group LLC	14,570	$46K	0.0%	-30.7%	0.039%
2/15/2023	State of Wisconsin Investment Board	15,000	$48K	0.0%	N/A	0.040%
2/15/2023	Schonfeld Strategic Advisors LLC	21,000	$67K	0.0%	-25.5%	0.056%
2/15/2023	Squarepoint Ops LLC	17,207	$55K	0.0%	N/A	0.045%
2/15/2023	Tang Capital Management LLC	485,234	$1.54M	0.2%	N/A	1.283%
2/15/2023	Millennium Management LLC	36,426	$0.12M	0.0%	+27.8%	0.096%
2/15/2023	Morgan Stanley	155,881	$0.49M	0.0%	-21.0%	0.412%
2/15/2023	AQR Capital Management LLC	29,952	$95K	0.0%	-86.4%	0.079%
2/14/2023	RA Capital Management L.P.	1,881,300	$5.96M	0.1%	+0.2%	4.973%
2/14/2023	Bristlecone Advisors LLC	696,629	$2.21M	0.3%	-0.6%	1.841%
2/14/2023	Two Sigma Investments LP	340,337	$1.08M	0.0%	-5.6%	0.900%
2/14/2023	Pura Vida Investments LLC	77,700	$0.25M	0.0%	-44.5%	0.205%
2/13/2023	Deutsche Bank AG	13,711	$43K	0.0%	-52.1%	0.036%
2/13/2023	Forefront Analytics LLC	22,350	$71K	0.0%	N/A	0.059%
2/13/2023	BML Capital Management LLC	714,763	$2.27M	2.2%	N/A	1.889%
2/13/2023	Panagora Asset Management Inc.	113,652	$0.36M	0.0%	+78.8%	0.300%
2/13/2023	Barclays PLC	208,089	$0.66M	0.0%	+24.8%	0.550%
2/13/2023	Renaissance Technologies LLC	82,100	$0.26M	0.0%	-65.1%	0.217%
2/13/2023	Geode Capital Management LLC	602,553	$1.91M	0.0%	+1.7%	1.593%
2/13/2023	GSA Capital Partners LLP	270,989	$0.86M	0.1%	+59.9%	0.716%
2/10/2023	Bank of America Corp DE	469,165	$1.49M	0.0%	-4.1%	1.240%
2/10/2023	Advisor Group Holdings Inc.	146,569	$0.46M	0.0%	+7.8%	0.387%
2/9/2023	Dimensional Fund Advisors LP	26,881	$85K	0.0%	+28.6%	0.071%
2/8/2023	UBS Group AG	102,844	$0.33M	0.0%	+57.9%	0.272%
2/2/2023	Bailard Inc.	45,094	$0.14M	0.0%	N/A	0.119%
1/25/2023	Lindbrook Capital LLC	11,407	$36K	0.0%	-32.6%	0.030%
1/19/2023	Rothschild Investment Corp IL	31,100	$99K	0.0%	N/A	0.082%
12/8/2022	Bank of New York Mellon Corp	109,796	$0.33M	0.0%	+16.4%	0.290%
11/16/2022	Balyasny Asset Management LLC	12,518	$37K	0.0%	N/A	0.033%
11/16/2022	Jane Street Group LLC	21,027	$63K	0.0%	-68.7%	0.056%
11/15/2022	Alliancebernstein L.P.	76,600	$0.23M	0.0%	+14.5%	0.202%
11/15/2022	State Street Corp	782,154	$2.32M	0.0%	-14.1%	2.068%
11/15/2022	Public Employees Retirement System of Ohio	33,500	$99K	0.0%	N/A	0.089%
11/15/2022	Jacobs Levy Equity Management Inc.	251,935	$0.75M	0.0%	N/A	0.666%
11/15/2022	Algert Global LLC	35,190	$0.11M	0.0%	N/A	0.093%
11/15/2022	Two Sigma Advisers LP	347,400	$1.03M	0.0%	+229.0%	0.918%
11/15/2022	Two Sigma Investments LP	360,643	$1.07M	0.0%	+29.5%	0.953%

Data available starting January 2016

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $1.97

$1.83

$1.99

50 Day Range

MA: $1.64

$1.39

$1.97

52 Week Range

Now: $1.97

$1.33

$4.41

Volume

298,247 shs

Average Volume

266,827 shs

Market Capitalization

$74.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Who are the company insiders with the largest holdings of Athira Pharma?: Athira Pharma's top insider shareholders include:
Perceptive Advisors Llc (Director)
Glenna Mileson (CFO)
Mark James Litton (CEO)
Andrew Gengos (Insider)
Hans Moebius (Insider)
Kelly A Romano (Director)
Mark Worthington (General Counsel)
Rachel Lenington (COO)
James A Johnson (Director)
Learn More about top insider investors at Athira Pharma.
Who are the major institutional investors of Athira Pharma?: Athira Pharma's top institutional investors include:
BML Capital Management LLC — 4.48%
Barclays PLC — 1.15%
Jacobs Levy Equity Management Inc. — 0.79%
GSA Capital Partners LLP — 0.78%
Nan Fung Group Holdings Ltd — 0.47%
Laird Norton Trust Company LLC — 0.47%
Learn More about top institutional investors of Athira Pharma stock.
Which major investors are selling Athira Pharma stock?: During the previous quarter, ATHA stock was sold by these institutional investors:
BML Capital Management LLC
Acadian Asset Management LLC
GSA Capital Partners LLP
Which major investors are buying Athira Pharma stock?: Within the previous quarter, ATHA stock was acquired by institutional investors including:
Barclays PLC
Nan Fung Group Holdings Ltd
Acuitas Investments LLC
Jacobs Levy Equity Management Inc.
UBS Group AG
Clarius Group LLC
Laird Norton Trust Company LLC
Marquette Asset Management LLC
During the last year, these company insiders have bought Athira Pharma stock:
Perceptive Advisors Llc (Director)
Glenna Mileson (CFO)
Mark James Litton (CEO)
Andrew Gengos (Insider)
Hans Moebius (Insider)
Kelly A Romano (Director)
Learn More investors buying Athira Pharma stock.